Ray Ozzie, Microsoft’s chief software architect, announced today the company is forming a new laboratory called Future Social Experience Labs, or FUSE Labs, which will focus on aspects of “social computing” beyond just communication and collaboration. The move is part of a wider restructuring of Microsoft’s labs: FUSE Labs is a merger between the Creative Systems Group at Microsoft Research in Redmond, WA; Rich Media Labs; and Startup Labs in Cambridge, MA. As part of the announcement, Ozzie said Reed Sturtevant, the founding managing director of Startup Labs for the past two years, is leaving the company to pursue other interests.

FUSE Labs will be led by Lili Cheng, a 14-year Microsoft veteran who most recently headed the Creative Systems Group and previously managed the user experience teams for Windows Vista. Before joining Microsoft, Cheng worked at Apple Computer in the human interface-advanced technology group, where she worked on QuickTime VR and QuickTime Conferencing products. Cheng is now general manager of FUSE Labs (in Redmond) and will report directly to Ozzie. “I’ve known Lili for many years, and have long been impressed by her vision and ability to create; to engage yet to also inspire; to lead; to make tough choices; to deliver,” Ozzie said in a memo to Microsoft staff.

Ozzie said he has “refined the missions” of Microsoft’s labs, in part because of “changing business conditions.” From his memo, it sounds like the goal of the new lab is to apply research in social computing (things like user interfaces, social networks, and human behavior) to help develop new products in the areas of entertainment, productivity, and teamwork—as well as to explore how Microsoft can extend the ways people use computer operating systems.

“The three groups being combined have concrete skills and code in areas where ‘social’ meets sharing; where ‘social’ meets real-time; where ‘social’ meets media; where ‘social’ meets search; where ‘social’ meets the cloud plus three screens and a world of devices,” he said. (See more on Ozzie’s three-screen vision here.)

It also sounds like the reorganization is meant to focus the impact of social computing research more immediately on the company’s product pipeline. “FUSE Labs will bring more coherence and capability to those advanced development projects where they’re already actively collaborating with product groups to help them succeed with ‘leapfrog’ efforts,” Ozzie said in his memo. “Working closely with [Microsoft Research] and across our divisions, the lab will prioritize efforts where its capabilities can be applied to areas where the company’s extant missions, structures, tempo or risk might otherwise cause us to miss a material threat or opportunity.”

Comments (1) | Reprints | Share:        

If you’re like me, you go through life with the vague hope that someday, technology will help you become a more efficient person. How often I’ve driven to the grocery store or the library to pick up one thing, knowing full well that there’s some other item I needed, but that I’ll never be able to locate it beneath the dust bunnies of my memory.

New tools for tidying up one’s brain come along all the time, of course: the File-o-fax of the 1990s gave way to the Palm Pilot, which eventually gave way to online services like Jott, Evernote, Remember the Milk, and Ta-Da List, and to the hundreds of personal productivity applications available for platforms like the iPhone. There’s even a whole website, Lifehacker, devoted to tracking such technologies.

But I’m still waiting for the über-application, the one central online repository that will allow me to a) file away all of the noteworthy bits of information coming in every day via e-mail, snail mail, catalogs, the blogs and websites I read, the mass media, billboards and posters, and the like, b) curate that information—that is, organize, annotate, tag, rearrange, and share it, and c) retrieve it when and where I really need it, whether I’m using my computer or my cell phone. The tool that currently comes closest to doing all that, for me, is Evernote, created by the Sunnyvale, CA, startup of the same name (I wrote a column about Evernote back in July). But now there’s a promising New England candidate, though it’s still in its embryonic stages: Springpad, an online notebook service launched in beta form last week by Boston-based Spring Partners.

Springpad is a system for creating customizable, task-oriented Web pages called, logically enough, springpads. To each springpad, you can add blocks of data such as text notes, to-do lists, contacts, calendar events, maps, and digital documents such as photos. You can build as many springpads as you want for the various tasks in your life. The company provides useful starting springpads designed for dozens of activities, from planning a vacation to tracking your pet’s medical records. There’s a powerful personal database system under the hood that allows you to tag, search, and share individual blocks, and Spring Partners—a 10-person, venture-backed startup located in Boston’s quaint Charlestown neighborhood —is working on add-ons such as an iPhone app and a Web clipper that will allow you to send information you find on the go or on the Web directly into your springpads.

If you go to Springpad right now, you might get the impression that it’s all about holiday planning—the same way MyPunchbowl is all about party planning or Geezeo is all about financial management (both of those life-tool startups happen to be located in the Boston area too). But the Thanksgiving and Christmas motif at Springpad is a bit misleading—and actually represents a marketing gamble of sorts for the startup.

As co-founder and CEO Jeff Janer explained to me when I visited the company Wednesday, the team had to start somewhere. Spring Partners—which consists almost entirely of transplants from Boston-based mobile advertising company Third Screen Media, acquired by AOL in 2007—has extremely ambitious plans for Springpad. Janer sees it as the central place for consumers, starting with the Web-savvy 25- to 35-year-old demographic, to organize all their life activities—shopping, chores, hobbies, eating out, exercise, travel, research, you name it. He describes it as a kind of anti-Facebook: a place to focus not on your social network but on yourself and all the tasks and information you have to manage.

But that’s a lot to explain to prospective users—and historically, quite a few super-duper personal information management tools have fallen victim to what Janer calls “blank slate syndrome,” the problem of having a great tool in front of you, but not knowing what to put into it.

So that’s why Springpad’s front pages are currently full of the kind of tips and advice you might find on the cover of the December issue of Better Homes & Gardens or Real Simple: an “8-week Holiday Preparation List,” a “Christmas Card Log,” a “Holiday Meal Planner.” The tips are linked to pre-built templates that guide users through the traditional tasks related to Thanksgiving, Chanukah, Christmas, and New Year’s celebrations. “The idea was to show people, in a focused way, how to survive the holidays,” says Janer. “Yes, there are all these other templates and features and functionalities available, but …Next Page »

Comments | Reprints | Share:        

Three of the world’s biggest drugmakers can agree on this—the research and development model for creating new drugs needs a serious kick in the rear. Pfizer, Merck, and Eli Lilly, through a collaboration hatched by Boston-based PureTech Ventures, have agreed to put $39 million into a new Boston company called Enlight Biosciences, whose job will be to create technologies that can enable researchers to make breakthrough drugs.

The venture has attracted very big names. The co-founders include Nobel Laureate H. Robert Horvitz, a biology professor at MIT, and Raju Kucherlapati, a genetics professor at Harvard Medical School who co-founded Millennium Pharmaceuticals and Abgenix. Enlight’s team also includes a pair of PureTech partners with loads of drug industry experience: Frank Douglas, former chief scientific officer at Aventis, and Bennett Shapiro, former executive vice president of basic research and worldwide licensing at Merck.

Enlight’s stated goal is to foster development of new technologies that can help the industry break out of its funk. Despite pumping tens of billions into research and development every year, including $44.5 billion last year according to an industry trade group, the pharmaceutical industry gets a lousy return on that investment. Only 19 new drugs were approved by the U.S. FDA last year, the fewest in 24 years. An estimated one out of every 10 drugs that enters clinical trials ever makes it through the gauntlet of tests to become a marketed product.

“The biopharmaceutical industry has a great need for innovative enabling technologies that will catalyze fundamental transformation of the drug discovery and development process,” said Steven Paul, executive vice president of science and technology for Eli Lilly, in a statement. “A collaborative entrepreneurial initiative such as Enlight that is dedicated to such technological innovation in R&D meets that need in an ideal way.”

Historical examples of what the founders see as enabling technologies are polymerase-chain reaction machines that do DNA analysis; genetic engineering techniques that use more human DNA than mouse DNA, and therefore make better-tolerated drugs; and RNA interference, or gene silencing technologies, that can attack a disease closer to its root cause.

“Going forward, the idea is to find the next RNAi,” says Daphne Zohar, managing partner of PureTech and a board member of Enlight (as well as an Xconomist), who credits Merck senior vice president Mervyn Turner with really embracing the idea and in effect sponsoring the collaboration. “The idea is provide technologies that bridge across all the stages of drug discovery, development, and patient care, therefore reducing failure rate of drugs and increasing the probability that innovative new medicine can reach patients in a more capital-efficient way—so that it actually eventually affects the cost of the medicines.”

To that end, Enlight will specifically look at ways to better connect animal testing, human clinical trials, and real-world medical practice. Programs have already started in molecular imaging that can predict how humans respond to drugs, better formulations of biotechnology medicines and new drug delivery techniques, the company said.

One reason the drugmakers agreed to team up? Because venture capitalists aren’t bankrolling as many breakthrough technologies that drugmakers can benefit from as they once did. The shift to investment in drug candidates in late stages of development means that “important technologies that could be of great strategic impact to the pharmaceutical industry are not being commercialized,” Enlight said in its statement.

Comments (5) | Reprints | Share: